Ed. Note:  The following is a press release issued by Pfizer, Inc.

Pfizer Submits New Drug Application for Pregabalin for the Treatment Of Neuropathic Pain, Generalized Anxiety Disorder and Partial Seizures
Friday October 31, 8:47 am ET

NEW YORK, Oct. 31 -- Pfizer Inc announced today that it has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration seeking approval for pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and herpes zoster (post-herpetic neuralgia), generalized anxiety disorder and adjunctive therapy for partial seizures in patients with epilepsy.

Developed by Pfizer, pregabalin has a unique mechanism of action for potential treatment of certain neurologic and psychiatric disorders. Neuropathic pain and generalized anxiety disorder are highly prevalent, under- diagnosed and under-treated conditions. There is currently no approved treatment on the market for neuropathic pain associated with DPN.

"Our New Drug Application for pregabalin is supported by clinical studies involving more than 10,000 patients. In the area of neuropathic pain where current treatment options are limited, pregabalin's clinical program represents the largest and most robust undertaken to date," said Dr. John LaMattina, president of Pfizer Global Research and Development. "Our submission for pregabalin is another important step in fulfilling our goal of filing 20 major NDAs in the five-year period ending in 2006." Earlier this year, Pfizer filed with European regulatory authorities to seek approval for the use of pregabalin in the treatment of neuropathic pain and as an adjunctive therapy for partial seizures.

Source: Pfizer Inc

Back to Table of Contents

Pfizer, Inc.

• World Headquarters in New York, NY

• Over 120,000 employees worldwide

• 2002 Revenue: $32.4 Billion

• 2003 Research and Development Budget: $7.1B

• Mission Statement:
  We will become the world's most valued company to patients, customers, colleagues, investors, business partners, and the communities where we work and live.

• Purpose Statement:
  We dedicate ourselves to humanity's quest for longer, healthier, happier lives through innovation in pharmaceutical, consumer, and animal health products.

• Products include:  Celebrex, Neurontin, Zoloft, Sudafed, Benadryl, Neosporin

Source:  Pfizer web site